Savant Capital LLC Grows Holdings in Neurocrine Biosciences, Inc. $NBIX

Savant Capital LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 57.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 36,659 shares of the company’s stock after buying an additional 13,417 shares during the period. Savant Capital LLC’s holdings in Neurocrine Biosciences were worth $5,146,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Envestnet Asset Management Inc. lifted its stake in shares of Neurocrine Biosciences by 2.4% in the third quarter. Envestnet Asset Management Inc. now owns 202,846 shares of the company’s stock worth $28,476,000 after acquiring an additional 4,807 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in Neurocrine Biosciences by 52.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,005 shares of the company’s stock worth $281,000 after purchasing an additional 693 shares during the last quarter. Peak Retirement Planning Inc. raised its position in shares of Neurocrine Biosciences by 23.7% in the 3rd quarter. Peak Retirement Planning Inc. now owns 14,711 shares of the company’s stock valued at $2,065,000 after purchasing an additional 2,818 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Neurocrine Biosciences by 17.3% during the 3rd quarter. Jones Financial Companies Lllp now owns 704 shares of the company’s stock valued at $100,000 after buying an additional 104 shares during the last quarter. Finally, State of Wyoming boosted its stake in shares of Neurocrine Biosciences by 78.8% during the 3rd quarter. State of Wyoming now owns 2,987 shares of the company’s stock valued at $419,000 after buying an additional 1,316 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock opened at $137.93 on Friday. The stock has a fifty day moving average of $142.42 and a two-hundred day moving average of $140.34. The firm has a market capitalization of $13.75 billion, a PE ratio of 33.00, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31. Neurocrine Biosciences, Inc. has a 1 year low of $84.23 and a 1 year high of $160.18.

Analyst Upgrades and Downgrades

NBIX has been the subject of several research analyst reports. Truist Financial dropped their target price on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. HC Wainwright boosted their price objective on Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Morgan Stanley reiterated an “equal weight” rating and issued a $175.00 target price (up previously from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. Zacks Research downgraded Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Finally, Royal Bank Of Canada raised their price objective on Neurocrine Biosciences from $160.00 to $180.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.25.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 1,190 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $155.09, for a total value of $184,557.10. Following the transaction, the director owned 6,239 shares in the company, valued at $967,606.51. This represents a 16.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kyle Gano sold 36,400 shares of the business’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the transaction, the chief executive officer owned 140,407 shares in the company, valued at approximately $18,632,008.90. This represents a 20.59% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 61,966 shares of company stock valued at $8,625,166. 4.80% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.